Health and Healthcare
2 Big Positive Developments in the COVID-19 Vaccine Race
Published:
As 2020 begins to wind down, some COVID-19 stocks are almost at the end of the journey for developing a treatment and vaccine. In fact, two companies have made very strong strides toward the finish line with recent developments.
Moderna Inc. (NASDAQ: MRNA) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Moderna announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273 in the New England Journal of Medicine. Overall, the data suggested that this vaccine candidate can generate neutralizing antibodies in older and elderly adults at levels comparable to those in young adults.
The analysis of this data found that the 25 µg and 100 µg dose levels were generally well tolerated in both age cohorts. Also, immune responses were dose-dependent with the 100 µg dose eliciting higher binding and neutralizing antibody titers, supporting the selection of the 100 µg dose for further study in the Phase 3 trial.
So far, the U.S. government has purchased 100 million doses of mRNA-1273, with an option to purchase an additional 400 million doses.
Moderna stock closed Tuesday at $70.52, in a 52-week range of $13.53 to $95.21. The consensus price target is $92.54. Following the announcement, the stock was up about 3% at $72.86 in early trading indications Wednesday.
Regeneron announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2. Overall, the data demonstrated that REGN-COV2 reduced the viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19.
Perhaps the greatest treatment benefit was in patients who had not mounted their own effective immune response, which suggests that REGN-COV2 could provide a therapeutic substitute for the naturally occurring immune response. These patients were less likely to clear the virus on their own and were at greater risk for prolonged symptoms.
As it stands, more than 2,000 people have been enrolled across the REGN-COV2 development program, and no unexpected safety findings have been reported by the Independent Data Monitoring Committee.
Regeneron stock last closed at $573.61, in a 52-week range of $272.26 to $664.64. Analysts have a consensus target of $674.63. The stock was up about 2% at $582.79 in early trading indications Wednesday.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
